EPAS1 and cancer: Nevertheless, as the links between hypoxia and HIF stabilisation in PPGL cancers are too strong, it remains something to be considered—especially given the ongoing clinical trials evaluating agents that target drivers and effectors of the pseudohypoxic phenotype: the VEGFA receptor and HIF2α (Toledo 2017).